Navigation Links
Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences

CHAPEL HILL, N.C., March 30, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced presentations at two upcoming investor conferences.  Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at the Needham & Company 10th Annual Healthcare Conference at 10 a.m. EDT, April 6, at The New York Palace Hotel in New York City.  Mark Hahn, chief financial officer of Cempra, will also be in attendance.  Dr. Fernandes will also present at the BioCentury Future Leaders in the Biotech Industry at 3 p.m. EDT, April 15 at the Millennium Broadway Hotel & Conference Center in New York City.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTATM for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251

SOURCE Cempra Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
2. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
3. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
4. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
5. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
7. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
8. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
9. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
10. Isis Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
11. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):